User:Steve7233/SPIRIT 2

This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft.

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs
This page was last edited by Timrollpickering (talk | contribs) 5 years ago. (Update timer)

Finished writing a draft article? Are you ready to request an experienced editor review it for possible inclusion in Wikipedia? Submit your draft for review!

SPIRIT 2 is a randomized phase 3 clinical in patients with chronic myeloid leukaemia being conducted in the United Kingdom. The study compares the use of imatinib (the standard of care for CML Patients in the UK since 2003) with dasatinib, a second generation tyrosine kinase inhibitor, in patientd newly diagnosed with CML. It is the only first-line study to have long term (in this case 5 year) survival as the primary endpoint.

References

External links

example.com